Literature DB >> 20203497

Overlap between irritable bowel syndrome and inflammatory bowel disease.

Robin C Spiller1.   

Abstract

While recent studies have indicated that the colonic mucosa in irritable bowel syndrome (IBS) shows an increase in inflammatory cells, this 'inflammation' is quantitatively less than in inflammatory bowel disease (IBD) and of a different nature with a predominance of mast cells, particularly in female patients. Inflammation can arise via numerous pathways including infection, stress, food allergy and changes in gut microbiota. Low-grade mucosal inflammation throughout the colon and including the terminal ileum can be seen for many months after an attack of acute gastroenteritis and is a feature of post-infective IBS. Measurements of gut permeability also show a prolonged increase in both the small and large bowel in both post-infective IBS and IBS with diarrhoea predominance. This has been linked to visceral hypersensitivity, but whether this is causal or an epiphenomenon remains uncertain. Studying the risk factors for post-infective IBS has shown the importance of both local and microbiological factors, as well as psychological factors, including adverse life events, anxiety and depression. Stress in both animals and humans can activate mast cells, which (by increasing gut permeability) may allow activation of the systemic immune system. Demonstration of the importance of the low-grade inflammation observed awaits definitive large scale trials of agents designed to specifically reverse these changes. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20203497     DOI: 10.1159/000268121

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  6 in total

Review 1.  Connecting the dots: could microbial translocation explain commonly reported symptoms in HIV disease?

Authors:  Natalie L Wilson; David E Vance; Linda D Moneyham; James L Raper; Michael J Mugavero; Sonya L Heath; Mirjam-Colette Kempf
Journal:  J Assoc Nurses AIDS Care       Date:  2014-07-22       Impact factor: 1.354

Review 2.  Refractory inflammatory bowel disease-could it be an irritable bowel?

Authors:  Jie Meng; Anurag Agrawal; Peter J Whorwell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-09-11       Impact factor: 46.802

3.  A magic pill? A qualitative analysis of patients' views on the role of antidepressant therapy in inflammatory bowel disease (IBD).

Authors:  Antonina A Mikocka-Walus; Andrea L Gordon; Benjamin J Stewart; Jane M Andrews
Journal:  BMC Gastroenterol       Date:  2012-07-20       Impact factor: 3.067

4.  Simple pain measures reveal psycho-social pathology in patients with Crohn's disease.

Authors:  Shmuel Odes; Michael Friger; Ruslan Sergienko; Doron Schwartz; Orly Sarid; Vered Slonim-Nevo; Terri Singer; Elena Chernin; Hillel Vardi; Dan Greenberg
Journal:  World J Gastroenterol       Date:  2017-02-14       Impact factor: 5.742

Review 5.  Gut microbiota as potential orchestrators of irritable bowel syndrome.

Authors:  Sean M P Bennet; Lena Ohman; Magnus Simren
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

6.  Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study.

Authors:  Hamed Daghaghzadeh; Fateme Naji; Hamid Afshar; Mohammad Reza Sharbafchi; Awat Feizi; Mohsen Maroufi; Mahshid Tabatabaeeyan; Peyman Adibi; Hamid Tavakoli
Journal:  J Res Med Sci       Date:  2015-06       Impact factor: 1.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.